5-butyl-9-methylphenanthridin-6(5H)-one | 1053188-51-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 5-butyl-9-methylphenanthridin-6(5H)-one
• 英文别名: 5-butyl-9-methylphenanthridin-6-one
• CAS: 1053188-51-4
• 化学式: C₁₈H₁₉NO
• 分子量: 265.355
• InChiKey: LBOXXSPAPGBTGY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  在 palladium diacetate 、 caesium carbonate 、 tricyclohexylphosphine tetrafluoroborate 作用下， 以 N,N-二甲基乙酰胺 为溶剂， 生成 5-butyl-9-methylphenanthridin-6(5H)-one
  参考文献：
  名称：

  Structural development studies of anti-hepatitis C virus agents with a phenanthridinone skeleton

  摘要：

  A phenanthridinone skeleton was derived from our previous researches on thalidomide and retinoids as a multi-template for generation of anti-viral lead compounds. Structural development studies focusing on anti-hepatitis C virus activity afforded 5-butyl-2-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenanthridin-6(5H)-one (10) and 5-butylbenzo[b] phenanthridin-6(5H)-one(39), which showed EC50 values of approximately 3.7 and 3.2 mu M, respectively. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2010.02.057

文献信息

• Samarium(II)-Mediated Spirocyclization by Intramolecular Aryl Radical Addition onto an Aromatic Ring
  作者：Hiroki Iwasaki、Toru Eguchi、Nozomi Tsutsui、Hiroaki Ohno、Tetsuaki Tanaka

  DOI：10.1021/jo800656a

  日期：2008.9.19

  Samarium(II)-mediated spirocyclization by intramolecular addition of aryl radicals onto an aromatic ring was achieved by the reaction of N-(2-iodophenyl)-N-alkylbenzamides with SmI2 in the presence of HMPA, yielding spirocyclic indolin-2-one derivatives. The ether congeners afford spirocyclic benzofuran derivatives in moderate yields by aryl radical addition onto a benzene ring without having an electron-withdrawing

  N-（2-碘苯基）-N-烷基苯甲酰胺与SmI2在HMPA存在下反应，通过在芳环上分子内加成芳基，将mar（II）介导的螺环化反应，生成螺环吲哚-2-酮衍生物。醚同类物通过在不具有吸电子基团的情况下将芳基自由基加成到苯环上而以中等收率得到螺环苯并呋喃衍生物。还描述了与其他芳基如萘和吲哚环的反应。
• THERAPEUTIC AGENT FOR HEPATITIS C
  申请人：Baba Masanori

  公开号：US20120316342A1

  公开（公告）日：2012-12-13

  This invention provides a therapeutic agent for hepatitis C comprising, as an active ingredient, a compound having anti-HCV activity useful in treatment of hepatitis C. The therapeutic agent for hepatitis C comprises, as an active ingredient, a compound represented by formula (I) or a pharmaceutically acceptable salt thereof.

  这项发明提供了一种治疗丙型肝炎的药剂，其活性成分为具有抗丙型肝炎病毒活性的化合物，可用于治疗丙型肝炎。治疗丙型肝炎的药剂的活性成分包括由式（I）表示的化合物或其药用可接受的盐。
• Structural development studies of anti-hepatitis C virus agents with a phenanthridinone skeleton
  作者：Masahiko Nakamura、Atsushi Aoyama、Mohammed T.A. Salim、Mika Okamoto、Masanori Baba、Hiroyuki Miyachi、Yuichi Hashimoto、Hiroshi Aoyama

  DOI：10.1016/j.bmc.2010.02.057

  日期：2010.4

  A phenanthridinone skeleton was derived from our previous researches on thalidomide and retinoids as a multi-template for generation of anti-viral lead compounds. Structural development studies focusing on anti-hepatitis C virus activity afforded 5-butyl-2-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenanthridin-6(5H)-one (10) and 5-butylbenzo[b] phenanthridin-6(5H)-one(39), which showed EC50 values of approximately 3.7 and 3.2 mu M, respectively. (C) 2010 Elsevier Ltd. All rights reserved.